Starting Dose of Intuniv for an 8-Year-Old
Begin with 1 mg once daily, taken either in the morning or evening, and do not exceed this starting dose regardless of the child's weight. 1
Dosing Algorithm
The FDA-approved dosing for Intuniv (guanfacine extended-release) in children follows a structured titration approach:
- Initial dose: 1 mg once daily 1
- Titration: Increase in increments of no more than 1 mg per week 1
- Target dose range: 1-4 mg once daily 1
- Weight-based consideration: While improvements are observed starting at 0.05-0.08 mg/kg once daily, with doses up to 0.12 mg/kg potentially providing additional benefit, you still begin at 1 mg regardless 1
For an 8-year-old child (typically weighing 20-30 kg), the 1 mg starting dose represents approximately 0.03-0.05 mg/kg, which is appropriately conservative given the medication's cardiovascular effects.
Critical Administration Details
Do not crush, chew, or break the tablets — they must be swallowed whole 1. Avoid administration with high-fat meals due to increased drug exposure 1. The medication can be given either morning or evening based on tolerability and family preference 1.
Pre-Treatment Requirements
Before initiating Intuniv, you must:
- Obtain personal and family cardiac history (specifically asking about sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome) 2
- Measure baseline heart rate and blood pressure 1
- Consider ECG if any cardiac risk factors are present 2
Expected Cardiovascular Effects
Intuniv causes predictable decreases in blood pressure and heart rate that require monitoring 1:
- Maximum mean changes: -5 mmHg systolic, -3 mmHg diastolic, -6 bpm heart rate 1
- These changes are dose-dependent and typically occur within one week of reaching target dose 1
- Hypotension occurred in 7% of monotherapy patients (vs 3% placebo), including 1% with orthostatic hypotension 1
Monitor vital signs after each dose increase and periodically during maintenance therapy 1.
Common Adverse Effects to Anticipate
The most frequent side effects (≥5% and at least twice placebo rate) in monotherapy trials were 1:
- Somnolence (38% vs 12% placebo)
- Headache (24% vs 19%)
- Fatigue (14% vs 3%)
- Abdominal pain (11% vs 9%)
- Nausea (6% vs 2%)
- Lethargy (6% vs 3%)
Somnolence is dose-related and most commonly occurs during dose titration 3. In one study, 62.5% of children experienced sedation/somnolence, but 63.5% of these cases resolved before the end of treatment 3.
Critical Safety Warning
Never abruptly discontinue Intuniv — rebound hypertension can occur 2. When stopping, taper in decrements of no more than 1 mg every 3-7 days 1.
Context Within ADHD Treatment
While stimulants remain first-line for ADHD in school-age children, Intuniv (along with extended-release clonidine) has FDA approval both as monotherapy and as adjunctive therapy with stimulants 2. The 2019 AAP guidelines note that nonstimulants like guanfacine have an extremely low risk of serious cardiovascular events, similar to stimulants 2.